| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | General Assembly Proposed Bill No. 737 | |
| 2 | 2 | January Session, 2017 LCO No. 502 | |
| 3 | 3 | *00502* | |
| 4 | 4 | Referred to Committee on GENERAL LAW | |
| 5 | 5 | Introduced by: | |
| 6 | 6 | SEN. KENNEDY, 12th Dist. | |
| 7 | 7 | ||
| 8 | 8 | General Assembly | |
| 9 | 9 | ||
| 10 | 10 | Proposed Bill No. 737 | |
| 11 | 11 | ||
| 12 | 12 | January Session, 2017 | |
| 13 | 13 | ||
| 14 | 14 | LCO No. 502 | |
| 15 | 15 | ||
| 16 | 16 | *00502* | |
| 17 | 17 | ||
| 18 | 18 | Referred to Committee on GENERAL LAW | |
| 19 | 19 | ||
| 20 | 20 | Introduced by: | |
| 21 | 21 | ||
| 22 | 22 | SEN. KENNEDY, 12th Dist. | |
| 23 | 23 | ||
| 24 | 24 | AN ACT CONCERNING PRESCRIPTION DRUG COST TRANSPARENCY. | |
| 25 | 25 | ||
| 26 | 26 | Be it enacted by the Senate and House of Representatives in General Assembly convened: | |
| 27 | 27 | ||
| 28 | 28 | That the general statutes be amended to require every manufacturer of a prescription drug made available in the state to file a report regarding each such drug that contains the total cost for the production of the drug, including, but not limited to, (1) the total research and development costs paid by the manufacturer and by any predecessor of such manufacturer, (2) the total costs of clinical trials and other regulatory costs paid by the manufacturer and by any predecessor of such manufacturer, (3) the total costs for materials, manufacturing and administration of the drug, (4) any other costs associated with the acquisition of the drug, and (5) the total marketing and advertising costs for the promotion of the drug directly to potential prescribers and consumers. | |
| 29 | 29 | ||
| 30 | 30 | Statement of Purpose: | |
| 31 | 31 | ||
| 32 | 32 | To explore options to help reduce the high costs of prescription drugs and educate the public and state agencies that pay for prescription drugs as to the costs of such drugs. |